Angiotensin-converting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men

Hypertension

Volumn 56, Issue 3, 2010, Pages 364-368

  Matsumoto, Tetsuya ^a   Takashima, Hiroyuki ^a   Nakae, Ichiro ^a   Yamane, Tetsunobu ^a   Hayashi, Hideki ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

angiotensin converting enzyme inhibitor; bradykinin; coronary; sex; tissue plasminogen activator

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY SINUS; DOPPLER ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SERUM; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CORONARY ANGIOGRAPHY; CORONARY VESSELS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLIDINES; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77955982083     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.154278     Document Type: Article

References (28)

1. Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol. 2001;87:18C-24C.
2. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol. 2005;25:2470-2479.
3. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961-966.
4. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37:1565-1570.
5. Robinson SD, Ludlam CA, Boon NA, Newby DE. Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2007;27:1651-1656.
6. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plas-minogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
7. Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ. Angio-tensin-converting enzyme inhibition increases basal vascular tissue plas-minogen activator release in women but not in men. Arterioscler Thromb Vasc Biol. 2005;25:2435-2440.
8. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibri-nolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens. 2001;14:921-926.
9. Dielis AW, Smid M, Spronk HM, Houben AJ, Hamulyák K, Kroon AA, Ten Cate H, de Leeuw PW. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension. 2005;46:1236-1242.
10. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951-958.
11. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29: 2669-2680.
12. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, Yasuda Y, Ozawa T, Matsuo S, Kinoshita M, Horie M. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol. 2003;41:1373-1379.
13. Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.
14. Ridderstråle W, Ulfhammer E, Jern S, Hrafnkelsdottir T. Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. Hypertension. 2006;47:686-691.
15. Ohira N, Matsumoto T, Tamaki S, Takashima H, Tarutani Y, Yamane T, Yasuda Y, Horie M. Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin. Hypertens Res. 2004;27:39-45.
16. Erdos EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension. 2010;55:214-220.
17. Jern S, Wall U, Bergbrant A, Selin-Sjogren L, Jern C. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler Thromb Vasc Biol. 1997;17: 3376-3383. (Pubitemid 28028545)
18. Tarutani Y, Matsumoto T, Takashima H, Yamane T, Horie M. Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin. Hypertens Res. 2005; 28:59-66.
19. Van Guilder GP, Hoetzer GL, Smith DT, Irmiger HM, Greiner JJ, Stauffer BL, DeSouza CA. Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol Endocrinol Metab. 2005;289:E807-E813.
20. Takashima H, Matsumoto T, Nakae I, Yamane T, Horie M. Cigarette smoking impairs bradykinin-stimulated tissue plasminogen activator release in human coronary circulation. Thromb Res. 2007;120:791-796.
21. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001;103:1936-1941.
22. Pellegrini MP, Newby DE, Maxwell S, Webb DJ. Short-term effects of transdermal nicotine on acute tissue plasminogen activator release in vivo in man. Cardiovasc Res. 2001;52:321-327.
23. Stauffer BL, Hoetzer GL, Van Guilder GP, Smith DT, Desouza CA. Gender differences in endothelial tissue-type plasminogen activator release in middle-aged adults. J Am Coll Cardiol. 2005;45:1547-1549.
24. Hoetzer GL, Stauffer BL, Irmiger HM, Ng M, Smith DT, DeSouza CA. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women. J Physiol. 2003; 551:721-728.
25. Pretorius M, Van Guilder GP, Guzman RJ, Luther JM, Brown NJ. 17/3-Estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women. Hypertension. 2008;51: 1190-1196.
26. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first athero-thrombotic events. Circulation. 2004;109:IV6-IV19.
27. Hrafnkelsdottir T, Gudnason T, Wall U, Jern C, Jern S. Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost. 2004;2:1960-1968.
28. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Nishiyama K. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol. 1997;20:441-445.